Hengrui Medicine drug added to breakthrough therapy list

Jiangsu Hengrui Medicine (SSE:600276) announced that its subsidiary, Suzhou Shengdiya Biomedicine, has a drug, SHR-A1811, a trastuzumab deruxtecan injection, placed on the proposed breakthrough therapy list by China's Center for Drug Evaluation (CDE). The drug is intended for HER2-expressing recurrent or metastatic cervical cancer after failure of platinum-based chemotherapy and immune checkpoint inhibitors. This marks the eighth time this drug candidate has been included on such a list. According to the announcement, cervical cancer ranks high among female reproductive system tumors in China, and there's an unmet need for drugs targeting HER2-expressing cervical cancer. The company has invested approximately 94.1 million yuan in the project to date. The company has cautioned investors about potential risks and uncertainty in the drug development process.